Biotechnology Industry Organization

FDA pandemic guidance is “unnecessarily burdensome”

FDA pandemic guidance is “unnecessarily burdensome”

By Nick Taylor

GSK, Genentech, BIO and PDA have stated that it is “unnecessarily burdensome” for pandemic production plans to conform to parts of 21 CFR and requested that the FDA revises its draft guidance.

Spotlight

Follow us

Webinars

Featured Suppliers

All